Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $32.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 68.16% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Friday, August 9th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. Stifel Nicolaus cut their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 9th. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, June 18th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $30.50.

Kura Oncology Stock Up 0.3 %

KURA stock opened at $19.03 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.77 and a beta of 0.88. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The stock has a fifty day moving average of $20.66 and a 200-day moving average of $20.70.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.04. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.53) EPS. As a group, equities research analysts predict that Kura Oncology will post -2.56 earnings per share for the current year.

Insider Activity

In other news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the sale, the insider now owns 68,979 shares in the company, valued at approximately $1,527,884.85. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently modified their holdings of the company. 1492 Capital Management LLC raised its holdings in shares of Kura Oncology by 1.0% during the 4th quarter. 1492 Capital Management LLC now owns 101,500 shares of the company’s stock valued at $1,460,000 after buying an additional 1,034 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after buying an additional 1,449 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in shares of Kura Oncology by 2.4% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after buying an additional 1,673 shares in the last quarter. Finally, Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after buying an additional 2,167 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.